These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

984 related articles for article (PubMed ID: 33484582)

  • 1. Janus kinase inhibitors for atopic dermatitis: a promising treatment modality.
    Cartron AM; Nguyen TH; Roh YS; Kwatra MM; Kwatra SG
    Clin Exp Dermatol; 2021 Jul; 46(5):820-824. PubMed ID: 33484582
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Baricitinib: therapeutic potential for moderate to severe atopic dermatitis.
    Calabrese L; Malvaso D; Chiricozzi A; Tambone S; D'Urso DF; Guerriero C; Peris K
    Expert Opin Investig Drugs; 2020 Oct; 29(10):1089-1098. PubMed ID: 32703039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib.
    Ferreira S; Guttman-Yassky E; Torres T
    Am J Clin Dermatol; 2020 Dec; 21(6):783-798. PubMed ID: 32776305
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Oral Janus Kinase Inhibitors in Pediatric Atopic Dermatitis.
    Navarrete-Rodríguez EM; Larenas-Linnemann D; Vidaurri de la Cruz H; Luna-Pech JA; Guevara Sanginés E
    Curr Allergy Asthma Rep; 2024 Sep; 24(9):485-496. PubMed ID: 39105881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nonclinical evaluations of deucravacitinib and Janus kinase inhibitors in homeostatic and inflammatory pathways.
    Johnson B; Cheng L; Koenitzer J; Catlett IM; Schafer P
    Front Immunol; 2024; 15():1437512. PubMed ID: 39403378
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and efficacy of upadacitinib in combination with topical corticosteroids in adolescents and adults with moderate-to-severe atopic dermatitis (AD Up): results from a randomised, double-blind, placebo-controlled, phase 3 trial.
    Reich K; Teixeira HD; de Bruin-Weller M; Bieber T; Soong W; Kabashima K; Werfel T; Zeng J; Huang X; Hu X; Hendrickson BA; Ladizinski B; Chu AD; Silverberg JI
    Lancet; 2021 Jun; 397(10290):2169-2181. PubMed ID: 34023009
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Real-world effectiveness and safety of Janus kinase 1 inhibitors for the treatment of moderate-to-severe atopic dermatitis: a single-center, prospective study in China.
    Chen Y; Cao Q; Peng C; Zhou B; Jiang Y; Chen X; Li J
    Front Med; 2024 Aug; 18(4):752-756. PubMed ID: 39012398
    [No Abstract]   [Full Text] [Related]  

  • 8. Janus kinase inhibitors and the changing landscape of vitiligo management: a scoping review.
    Utama A; Wijesinghe R; Thng S
    Int J Dermatol; 2024 Aug; 63(8):1020-1035. PubMed ID: 38610078
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Innovation in the treatment of atopic dermatitis: Emerging topical and oral Janus kinase inhibitors.
    Nakashima C; Yanagihara S; Otsuka A
    Allergol Int; 2022 Jan; 71(1):40-46. PubMed ID: 34815171
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Janus kinase inhibitors for the treatment of rheumatoid arthritis demonstrate similar profiles of in vitro cytokine receptor inhibition.
    Dowty ME; Lin TH; Jesson MI; Hegen M; Martin DA; Katkade V; Menon S; Telliez JB
    Pharmacol Res Perspect; 2019 Dec; 7(6):e00537. PubMed ID: 31832202
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Janus kinase inhibitors ruxolitinib and baricitinib impair glycoprotein-VI mediated platelet function.
    Parra-Izquierdo I; Melrose AR; Pang J; Lakshmanan HHS; Reitsma SE; Vavilapalli SH; Larson MK; Shatzel JJ; McCarty OJT; Aslan JE
    Platelets; 2022 Apr; 33(3):404-415. PubMed ID: 34097573
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Abrocitinib: a potential treatment for moderate-to-severe atopic dermatitis.
    Nezamololama N; Crowley EL; Gooderham MJ; Papp K
    Expert Opin Investig Drugs; 2020 Sep; 29(9):911-917. PubMed ID: 32741227
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Journal club: New small molecules for atopic dermatitis management.
    Lefevre MA; Mohme S; Alband N; Nogueira M; Rosell Diaz A; Rodriguez-Lomba E
    Eur J Dermatol; 2021 Dec; 31(6):849-852. PubMed ID: 35107077
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparative efficacy and safety of abrocitinib, baricitinib, and upadacitinib for moderate-to-severe atopic dermatitis: A network meta-analysis.
    Wan H; Jia H; Xia T; Zhang D
    Dermatol Ther; 2022 Sep; 35(9):e15636. PubMed ID: 35703351
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy and Safety of Baricitinib Combined With Topical Corticosteroids for Treatment of Moderate to Severe Atopic Dermatitis: A Randomized Clinical Trial.
    Reich K; Kabashima K; Peris K; Silverberg JI; Eichenfield LF; Bieber T; Kaszuba A; Kolodsick J; Yang FE; Gamalo M; Brinker DR; DeLozier AM; Janes JM; Nunes FP; Thyssen JP; Simpson EL
    JAMA Dermatol; 2020 Dec; 156(12):1333-1343. PubMed ID: 33001140
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
    Taylor PC
    Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The JAK1/2 inhibitor baricitinib suppresses eosinophil effector function and restricts allergen-induced airway eosinophilia.
    Luschnig P; Kienzl M; Roula D; Pilic J; Atallah R; Heinemann A; Sturm EM
    Biochem Pharmacol; 2021 Oct; 192():114690. PubMed ID: 34274356
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Once-daily upadacitinib versus placebo in adolescents and adults with moderate-to-severe atopic dermatitis (Measure Up 1 and Measure Up 2): results from two replicate double-blind, randomised controlled phase 3 trials.
    Guttman-Yassky E; Teixeira HD; Simpson EL; Papp KA; Pangan AL; Blauvelt A; Thaçi D; Chu CY; Hong HC; Katoh N; Paller AS; Calimlim B; Gu Y; Hu X; Liu M; Yang Y; Liu J; Tenorio AR; Chu AD; Irvine AD
    Lancet; 2021 Jun; 397(10290):2151-2168. PubMed ID: 34023008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The oral Janus kinase/spleen tyrosine kinase inhibitor ASN002 demonstrates efficacy and improves associated systemic inflammation in patients with moderate-to-severe atopic dermatitis: results from a randomized double-blind placebo-controlled study.
    Bissonnette R; Maari C; Forman S; Bhatia N; Lee M; Fowler J; Tyring S; Pariser D; Sofen H; Dhawan S; Zook M; Zammit DJ; Usansky H; Denis L; Rao N; Song T; Pavel AB; Guttman-Yassky E
    Br J Dermatol; 2019 Oct; 181(4):733-742. PubMed ID: 30919407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. JAK selectivity and the implications for clinical inhibition of pharmacodynamic cytokine signalling by filgotinib, upadacitinib, tofacitinib and baricitinib.
    Traves PG; Murray B; Campigotto F; Galien R; Meng A; Di Paolo JA
    Ann Rheum Dis; 2021 Jul; 80(7):865-875. PubMed ID: 33741556
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 50.